PL3352777T3 - Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona - Google Patents

Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona

Info

Publication number
PL3352777T3
PL3352777T3 PL16777596T PL16777596T PL3352777T3 PL 3352777 T3 PL3352777 T3 PL 3352777T3 PL 16777596 T PL16777596 T PL 16777596T PL 16777596 T PL16777596 T PL 16777596T PL 3352777 T3 PL3352777 T3 PL 3352777T3
Authority
PL
Poland
Prior art keywords
engrailed
dna
damage
treatment
patient suffering
Prior art date
Application number
PL16777596T
Other languages
English (en)
Inventor
Alain Prochiantz
Original Assignee
Centre National De La Recherche Scientifique
Institut National De La Santé Et De La Recherche Médicale (Inserm)
College De France
Sorbonne Université
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique, Institut National De La Santé Et De La Recherche Médicale (Inserm), College De France, Sorbonne Université filed Critical Centre National De La Recherche Scientifique
Publication of PL3352777T3 publication Critical patent/PL3352777T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL16777596T 2015-09-23 2016-09-23 Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona PL3352777T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306482 2015-09-23
PCT/EP2016/072675 WO2017071889A1 (en) 2015-09-23 2016-09-23 Homeoproteins for use in the treatment of neurodegenerative disorders
EP16777596.4A EP3352777B1 (en) 2015-09-23 2016-09-23 Engrailed for use in the treatment of dna-damage in a patient suffering from parkinson disease

Publications (1)

Publication Number Publication Date
PL3352777T3 true PL3352777T3 (pl) 2022-02-07

Family

ID=54207439

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21189549.5T PL3960195T3 (pl) 2015-09-23 2016-09-23 Engrailed do zastosowania w leczeniu stwardnienia zanikowego bocznego
PL16777596T PL3352777T3 (pl) 2015-09-23 2016-09-23 Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL21189549.5T PL3960195T3 (pl) 2015-09-23 2016-09-23 Engrailed do zastosowania w leczeniu stwardnienia zanikowego bocznego

Country Status (7)

Country Link
US (2) US20190247461A1 (pl)
EP (2) EP3960195B1 (pl)
JP (1) JP6860575B2 (pl)
CN (1) CN108289929A (pl)
ES (2) ES3010130T3 (pl)
PL (2) PL3960195T3 (pl)
WO (1) WO2017071889A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026503094A (ja) 2023-01-13 2026-01-27 ブレインエバー 安定化エングレイルドタンパク質水性組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662698A1 (fr) * 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
FR2897780B1 (fr) 2006-02-28 2008-05-23 Centre Nat Rech Scient Utilisation de la proteine a homeodomaine engrailed comme anxiolytique
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
FR2926023B1 (fr) 2008-01-09 2010-02-26 Centre Nat Rech Scient Utilisation d'une homoproteine de la famille bicoid pour le traitement du glaucome.
MX2012000541A (es) * 2009-07-13 2012-03-14 Univ Surrey Peptidos, polipeptidos y secuencias de acidos nucleicos terapeuticos.
WO2013128239A1 (en) 2012-02-29 2013-09-06 Centre National De La Recherche Scientifique Use of engrailed for increasing dopamine synthesis by dopaminergic neurons

Also Published As

Publication number Publication date
ES2895154T3 (es) 2022-02-17
US20210379144A1 (en) 2021-12-09
EP3960195B1 (en) 2025-01-08
JP2018536697A (ja) 2018-12-13
EP3960195A1 (en) 2022-03-02
JP6860575B2 (ja) 2021-04-14
WO2017071889A1 (en) 2017-05-04
ES3010130T3 (en) 2025-04-01
CN108289929A (zh) 2018-07-17
US20190247461A1 (en) 2019-08-15
EP3352777A1 (en) 2018-08-01
CA2999209A1 (en) 2017-05-04
EP3352777B1 (en) 2021-09-15
PL3960195T3 (pl) 2025-06-09

Similar Documents

Publication Publication Date Title
IL256175A (en) Using exosomes to treat the disease
PT3212233T (pt) Terapia combinada para o tratamento de doenças
SI3122878T1 (sl) MRNA terapija za zdravljenje očesnih bolezni
IL253945A0 (en) kdm1a inhibitors to treat the disease
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
IL263188B (en) Treatment for Parkinson's disease
GB2538923B (en) A therapeutic agent for use in the treatment of infections
PL3129483T3 (pl) Terapia skojarzona do leczenia chorób autoimmunologicznych
EP3096775A4 (en) Socs mimetics for the treatment of diseases
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
SI3548006T1 (sl) Sestava za uporabo pri zdravljenju črevesnih sprememb
PL3352777T3 (pl) Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona
IL251135A (en) A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment
HUE061056T2 (hu) Készítmény meddõség kezelésére nõi betegnél
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
IL272422A (en) Methods for treating diseases of the meninges
GB201603510D0 (en) Compositions for use in the treatment of neurological disease
ZA201807944B (en) Treatment for parkinson's disease
IL247732A0 (en) Perinase inhibitory peptides and their use in the treatment of clinical pathologies
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
GB201518052D0 (en) Parkinson's disease treatment
GB201621398D0 (en) Treatment of emt-associated disease